This is an X-PIL, which is a text only patient information leaflet, designed for people with sight problems.
Table of Contents
Konverge 20 mg/5 mg
Konverge 40 mg/5 mg
Konverge 40 mg/10 mg
Film-Coated Tablets
olmesartan medoxomil/amlodipine
1. What Konverge is and what it is used for 2. Before you take Konverge 3. How to take Konverge 4. Possible side effects 5. How to store Konverge 6. Further information
Konverge contains two substances called olmesartan medoxomil and amlodipine (as amlodipine besilate). Both of these substances help to control high blood pressure.
The actions of both these substances contribute to stopping the tightening of blood vessels, so that blood vessels relax and blood pressure decreases.
Konverge is used for the treatment of high blood pressure in patients whose blood pressure is not controlled enough with either olmesartan medoxomil or amlodipine alone.
Before you take these tablets, tell your doctor if you have any of the following health problems:
As with any medicine which reduces blood pressure, an excessive drop in blood pressure in patients with blood flow disturbances of the heart or brain could lead to a heart attack or stroke. Your doctor will therefore check your blood pressure carefully.
You must tell your doctor if you think that you are (or might become) pregnant. Konverge is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see section “Pregnancy and breast-feeding”).
Please tell your doctor or pharmacist if you are taking or have recently taken any of the following medicines:
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Konverge can be taken with or without food. Swallow the tablet with some fluid (such as one glass of water). If possible, take your daily dose at the same time each day, for example at breakfast time.
Konverge is not recommended for children and adolescents under the age of 18.
If you are over 65 years of age, your doctor will regularly check your blood pressure at any dose increase, to make sure that your blood pressure does not become too low.
As with other similar drugs the blood pressure lowering effect of Konverge can be somewhat less in black patients.
Pregnancy
You must tell your doctor if you think that you are (or might become) pregnant. Your doctor will normally advise you to stop taking Konverge before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Konverge. Konverge is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if it is used after the third month of pregnancy.
If you become pregnant during therapy with Konverge, please inform and see your physician without delay.
Breast-feeding
Tell your doctor if you are breast-feeding or about to start breast-feeding. Konverge is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.
Ask your doctor or pharmacist for advice before taking any medicine if you are pregnant or breast-feeding.
You may feel sleepy, sick or dizzy or get a headache while being treated for your high blood pressure. If this happens, do not drive or use machines until the symptoms wear off. Ask your doctor for advice.
Always take Konverge exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.
If you take more tablets than you should you may experience low blood pressure with symptoms such as dizziness; fast or slow heart beat.
If you take more tablets than you should or if a child accidentally swallows some, go to your doctor or nearest emergency department immediately and take your medicine pack or this leaflet with you.
If you forget to take a dose, take your normal dose on the following day as usual. Do not take any extra tablets to make up for the missed dose.
It is important to continue to take Konverge unless your doctor tells you to stop.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, Konverge can cause side effects, although not everybody gets them. If they do occur, they are often mild and do not require treatment to be stopped.
Allergic reactions, that may affect the whole body, with swelling of the face, mouth and/or larynx (voice box) together with itching and rash may occur during treatment with Konverge. If this happens stop taking Konverge and talk to your doctor immediately.
Konverge can cause the blood pressure to fall too low in susceptible individuals or as the result of an allergic reaction. This could cause severe light-headedness or fainting. If this happens stop taking Konverge, talk to your doctor immediately and lie down flat.
Common (affecting less than 1 in 10 patients):
Dizziness; headache; swelling of ankles, feet, legs, hands, or arms; tiredness.
Uncommon (affecting less than 1 in 100 patients):
Dizziness on standing up; lack of energy; tingling or numbness of hands or feet; vertigo; strong heart beat; fast heart beat; low blood pressure with symptoms such as dizziness, light-headedness; laboured breathing; cough; nausea; vomiting; indigestion; diarrhoea; constipation; dry mouth, upper abdominal pain; skin rash; muscle spasms; pain in arms and legs; back pain; feeling more of an urge to pass urine; sexual inactivity; inability to get or maintain an erection; weakness.
Some changes in blood test results have also been seen and include the following:
increased as well as decreased blood potassium levels, increased blood creatinine levels, increased uric acid levels, increases in a test of liver function (gamma glutamyl transferase levels).
Rare (affecting less than 1 in 1,000 patients):
Drug hypersensitivity; fainting; redness and warm feeling of the face; rash with hives; swelling of face.
Olmesartan medoxomil
Common (affecting less than 1 in 10 patients): Bronchitis; sore throat; runny or stuffy nose; cough; abdominal pain; stomach flu; diarrhoea; indigestion; nausea; pain in the joints or bones; back pain; blood in the urine; infection of the urinary tract; chest pain; flu-like symptoms; pain. Changes in blood test results as increased fat levels (hypertriglyceridaemia), blood urea or uric acid increased and increase in tests of liver and muscle function.
Reduced number of a type of blood cells, known as platelets, which can result in easily bruising or prolonged bleeding time; quick allergic reactions that may affect the whole body and may cause breathing problems as well as a rapid fall of blood pressure that may even lead to fainting (anaphylactic reactions); angina (pain or uncomfortable feeling in the chest, known as angina pectoris); itching; eruption of the skin; allergic skin rash; rash with hives; swelling of the face; muscular pain; feeling unwell.
Swelling of the face, mouth and/or larynx (voice box); acute kidney failure and kidney insufficiency; lethargy.
Amlodipine
Abdominal pain; nausea; ankle swelling; feeling sleepy; redness and warm feeling of the face.
Trouble sleeping; sleep disturbances; mood changes including feeling anxious; depression; irritability; shiver; taste changes; fainting; visual disturbances including double vision; ringing in the ears (tinnitus); worsening of angina pectoris (pain or uncomfortable feeling in the chest); runny or stuffy nose; loss of hair; purplish spots or patches on the skin due to small haemorrhages (purpura); discoloration of the skin; excessive sweating; eruption of the skin; itching; pain of joints or muscles; problems to pass urine; urge to pass urine at night; increased need to urinate (pass urine); breast enlargement in men; chest pain; pain, feeling unwell; increase or decrease in weight.
Confusion
Very rare (affecting less than 1 in 10,000 patients):
Reduction in the number of white cells in the blood, which could increase the risk of infections; a reduction in the number of a type of blood cells known as platelets, which can result in easily bruising or prolonged bleeding time; increase in blood glucose; increased tightness of muscles or increased resistance to passive movement (hypertonia); tingling or numbness of hands or feet; heart attack and irregular heartbeat; inflammation of blood vessels; inflammation of the liver or the pancreas; inflammation of stomach lining; thickening of gums; elevated liver enzymes; yellowing of the skin and eyes; increased sensitivity of the skin to light; allergic reactions (itching, rash, swelling of the face, mouth and/or larynx (voice box) together with itching and rash, other allergic conditions with inflammation and peeling of the skin, sometimes life-threatening).
If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Keep out of the reach and sight of children.
Do not use Konverge after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.
This medicinal product does not require any special storage condition.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
The active substances are olmesartan medoxomil and amlodipine (as besilate).
Each tablet contains 20 mg of olmesartan medoxomil and 5 mg amlodipine (as besilate).
Each tablet contains 40 mg of olmesartan medoxomil and 5 mg amlodipine (as besilate).
Each tablet contains 40 mg of olmesartan medoxomil and 10 mg amlodipine (as besilate).
Other ingredients are
Tablet core: Pregelatinised maize starch, silicified microcrystalline cellulose, croscarmellose sodium, magnesium stearate,
Tablet coat: polyvinyl alcohol, macrogol 3350, talc, titanium dioxide (E171) and iron (III) oxide (E172, Konverge 40 mg/ 5 mg and 40 mg/10 mg film coated tablets only).
Konverge 20 mg/5 mg film-coated tablets are white, round with C73 on one side.
Konverge 40 mg/5 mg film-coated tablets are cream, round with C75 on one side.
Konverge 40 mg/10 mg film-coated tablets are brownish-red, round with C77 on one side.
Konverge film-coated tablets are available in packs of 14, 28, 30, 56, 90, 98 and 10 x 28, 10 x 30 film-coated tablets and in packs with perforated unit dose blisters of 10, 50 and 500 film-coated tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Manufacturer
This medicinal product is authorized in the Member States of the EEA under the following names:
Austria: Amelior 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Belgium: Forzaten 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Bulgaria: Tespadan 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Cyprus: Orizal 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Czech Republic: Sintonyn 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Denmark: Alea 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Estonia: Sanoral 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Finland: Alea 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
France: Axeler 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Germany: Vocado 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Greece: Orizal 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Hungary: Duactan 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Iceland: Alea 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Ireland: Konverge 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Italy: Bivis 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Latvia: Sanoral 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Lithuania: Sanoral 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Luxembourg: Forzaten 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
The Netherlands: Belfor 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Malta: Konverge 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Norway: Alea 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Poland: Elestar 20 mg+5 mg, 40 mg+5 mg, 40 mg+10 mg
Portugal: Zolnor 20 mg+ 5 mg, 40 mg+5 mg, 40 mg+10 mg
Romania: Inovum 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Slovak Republic: Folgan 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Slovenia: Olectan 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
Spain: Balzak 20 mg/5 mg, 40 mg/5 mg, 40 mg/10 mg
This leaflet was last approved in 02/2011.
Link to this document from your website:http://www.medicines.ie/medicine/14444/XPIL/Konverge++(A.Menarini+Pharmaceuticals+Ltd+and+Daiichi+Sankyo+Ireland+Ltd)/